CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

pembrolizumab

Last Updated: April 14, 2021
Result type: Reports
Project Number: PC0250-000
Product Line: Reimbursement Review

Generic Name: pembrolizumab

Brand Name: Keytruda

Manufacturer: Merck Canada

Therapeutic Area: Esophageal carcinoma, gastroesophageal junction adenocarcinoma

Indications: ​First-line treatment of locally advanced unresectable or metastatic, carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients.

Manufacturer Requested Reimbursement Criteria1: ​First-line treatment of locally advanced unresectable or metastatic, carcinoma of the esophagus or HER-2 negative gastroesophageal junction adenocarcinoma in combination with platinum and fluoropyrimidine based chemotherapy, in adult patients.

Submission Type: Initial

Tumour Type: Head and Neck

Project Status: Pending

Call for patient/clinician input open: April 14, 2021

Call for patient/clinician input closed: June 4, 2021

Anticipated Date: May 26, 2021

Fee Schedule1: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Submit Feedback